Inspire HGNS denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for inspire hgns are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Inspire HGNS as Duplicate Therapy

UnitedHealthcare (UHC) may issue a duplicate-therapy denial for hypoglossal nerve stimulation when its clinical reviewers determine that you are already covered for or receiving treatment for obstructive sleep apnea — typically CPAP or another PAP device — and conclude that adding an HGNS implant duplicates an existing benefit. This reasoning is medically flawed when PAP therapy has failed or is not tolerable, and UHC's own published coverage determination for HGNS reflects this by listing PAP failure as a coverage criterion.

The key argument: Inspire HGNS is not an add-on to PAP therapy. It is a surgically implanted neurostimulation system prescribed specifically for patients in whom PAP therapy has been inadequate or not tolerated. When PAP has failed, the two therapies are not duplicates — they are sequential, with HGNS as a medically necessary alternative after first-line therapy has proven insufficient. UHC's own policy language, when read carefully, supports coverage of HGNS precisely because PAP failure is an expected precondition.

## Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written appeal within the deadline shown on your denial letter. For ERISA-governed employer plans, you are entitled to a full and fair review with access to all criteria relied upon.
• External review: After exhausting internal appeals, you may request independent external review, generally within approximately four months of the final internal denial.
• Expedited review: Available if your condition is urgent or deteriorating.
• Disclosure right: Request all clinical guidelines and criteria UHC relied upon in the duplicate-therapy determination.

## What to Gather

1. OSA diagnosis and severity — polysomnography confirming diagnosis, type, and severity classification from a sleep specialist. 2. PAP therapy failure documentation — objective PAP device download data showing usage hours and residual event indices; chart notes documenting the duration and outcome of the PAP trial, mask changes or other optimization attempts, and clinical conclusion of failure or intolerance. Include specific dates. 3. Prescriber letter — from your sleep physician and/or surgeon explicitly stating that PAP and HGNS are not duplicative treatments, that PAP therapy was inadequate for this patient, and that HGNS is the medically necessary next step — not a supplement. 4. UHC's published coverage determination — download UHC's current Coverage Determination Guideline for hypoglossal nerve stimulation/Inspire from uhcprovider.com or myuhc.com. Note any language listing PAP failure as a coverage criterion, as this directly counters the duplicate-therapy rationale. 5. Clinical severity and health impact — chart notes documenting how untreated or inadequately treated OSA is affecting your health.

## Criteria-Mapping Structure

| UHC Coverage Criterion (verbatim from guideline) | Evidence in Your Chart | |---|---| | [PAP failure or intolerance criterion — exact text] | [Download data, dates, physician failure note] | | [Any other listed criterion] | [Specific chart finding, date, clinician note] |

Close your appeal by citing UHC's own policy: it does not treat HGNS as duplicative of PAP therapy — to the contrary, it conditions coverage on PAP failure. The duplicate-therapy denial misapplies the policy to a situation it was designed to address.